Glenmark Pharmaceuticals Limited has scheduled its 48th Annual General Meeting (AGM) for Friday, September 11, 2026, at 2:00 p.m. IST, to be held exclusively through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting aims to transact business as outlined in the notice, including the approval of financial results for FY25-26 and the declaration of dividends. Shareholders must ensure their KYC details are updated to receive dividends electronically, as mandated by recent regulatory circulars.

The meeting is convened in compliance with the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025. Electronic copies of the AGM notice and Integrated Annual Report for FY25-26 will be dispatched to members with registered email IDs as of July 31, 2026. Physical copies can be requested via email to complianceofficer@glenmarkpharma.com .

Key Dates and Voting Schedule

Shareholders are required to adhere to specific timelines for e-voting and dividend eligibility. The cut-off date for determining voting eligibility is Friday, September 04, 2026. Remote e-voting will commence on Tuesday, September 08, 2026, at 9:00 a.m. IST and conclude on Thursday, September 10, 2026, at 5:00 p.m. IST. Votes cast during this window cannot be altered or recast during the live AGM session.

Dividend and KYC Compliance

The Board of Directors, in its meeting on May 29, 2026, recommended a dividend of ₹2.5 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the AGM. If approved, the dividend will be paid on or after Monday, September 14, 2026, within 30 days of declaration. Payment will be made exclusively through electronic transfer modes to members holding shares as of the record date, August 31, 2026.

Glenmark Pharmaceuticals emphasizes strict adherence to KYC norms. Members holding physical shares must update their PAN, contact details, mobile number, bank account, and signature via Form ISR-1 and ISR-2 submitted to KFin Technologies Limited. Failure to update these details before the cut-off may result in dividend payments being restricted to periods from April 1, 2024, onwards until compliance is achieved. Demat holders are advised to update bank details directly with their Depository Participants.

Glenmark Pharmaceuticals Limited has uploaded the transcript of its first quarter fiscal year 2027 earnings call to its official website, offering investors a comprehensive written record of management’s discussion on financial performance. The conference call took place on August 3, 2026, covering the quarter ended June 30, 2026. This disclosure ensures transparency and allows stakeholders to review the detailed discussion on operational and financial metrics presented during the event.

The company submitted this information to the National Stock Exchange of India Limited and BSE Limited in compliance with regulatory requirements. Specifically, the disclosure was made pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely dissemination of material information to listed entities’ shareholders and the broader market.

Disciplinary Compliance Details

Glenmark Pharmaceuticals Limited confirmed that the transcript is hosted at a specific URL on its corporate domain. The reference number for this communication is 41/26-27. The submission was digitally signed by Rashmi Khandelwal, the Company Secretary & Compliance Officer, on August 5, 2026. Her ACS number is 28839. The company’s registered office is located in Mumbai, and it operates under CIN L24299MH1977PLC019982.

Accessing the Transcript

Investors and analysts can access the transcript directly via the link provided in the exchange filing. The document is titled "Glenmark-Earnings-Aug03-2026-Revised.pdf" and is stored in the Financials/Quarterly section of the Glenmark Pharmaceuticals website. This direct access mechanism aligns with best practices for investor relations, ensuring that all market participants have equal opportunity to review management’s perspective on the quarter’s results without delay.